AR101811A1 - Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular - Google Patents

Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular

Info

Publication number
AR101811A1
AR101811A1 ARP150102894A ARP150102894A AR101811A1 AR 101811 A1 AR101811 A1 AR 101811A1 AR P150102894 A ARP150102894 A AR P150102894A AR P150102894 A ARP150102894 A AR P150102894A AR 101811 A1 AR101811 A1 AR 101811A1
Authority
AR
Argentina
Prior art keywords
monoclonal antibody
enzymatic activity
humanized monoclonal
lipase
antibody inhibiting
Prior art date
Application number
ARP150102894A
Other languages
English (en)
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55459146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR101811(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of AR101811A1 publication Critical patent/AR101811A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)

Abstract

Un anticuerpo monoclonal humanizado, o un fragmento de este, que inhibe de manera selectiva la actividad enzimática de la lipasa endotelial vascular, y composiciones farmacéuticas que lo contienen como ingrediente activo, útiles para el tratamiento de la arterioesclerosis o el síndrome metabólico. Reivindicación 1: Un anticuerpo monoclonal humanizado caracterizado porque inhibe la actividad enzimática de la lipasa endotelial vascular, o un fragmento de anticuerpo de aquel, en donde aquel reconoce residuos de aminoácidos en las posiciones 1 a 157 en la secuencia de aminoácidos de SEQ ID Nº 1.
ARP150102894A 2014-09-11 2015-09-10 Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular AR101811A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014184710 2014-09-11

Publications (1)

Publication Number Publication Date
AR101811A1 true AR101811A1 (es) 2017-01-11

Family

ID=55459146

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102894A AR101811A1 (es) 2014-09-11 2015-09-10 Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular

Country Status (19)

Country Link
US (2) US10570215B2 (es)
EP (1) EP3192813A4 (es)
JP (2) JP6635599B2 (es)
KR (1) KR102520286B1 (es)
CN (1) CN107074963B (es)
AR (1) AR101811A1 (es)
AU (1) AU2015313179B2 (es)
BR (1) BR112017004429A2 (es)
CA (1) CA2960994A1 (es)
CL (1) CL2017000595A1 (es)
EA (1) EA036324B1 (es)
IL (1) IL250981B (es)
MX (1) MX2017002968A (es)
MY (1) MY181835A (es)
PH (1) PH12017500461A1 (es)
SG (2) SG11201701762VA (es)
TW (2) TWI688575B (es)
WO (1) WO2016039402A1 (es)
ZA (1) ZA201702489B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017017049A (es) * 2015-06-30 2018-03-06 Seattle Genetics Inc Anticuerpos anti antigeno de celulas nk y linfocitos t y b (ntb-a) y composiciones y metodos relacionados.
CA3066514A1 (en) * 2017-07-10 2019-01-17 Innate Pharma Siglec-9-neutralizing antibodies
US20200347130A1 (en) * 2017-11-10 2020-11-05 Jiangsu Hengrui Medicine Co., Ltd. CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
US20230045712A1 (en) * 2019-11-07 2023-02-09 Medimmune, Llc Endothelial lipase antibodies for the treatment of cardiovascular diseases
CN115297838A (zh) * 2020-02-24 2022-11-04 麦迪穆医学免疫有限责任公司 抗内皮脂肪酶抗体的制剂
WO2022095934A1 (zh) * 2020-11-05 2022-05-12 上海津曼特生物科技有限公司 抗Siglec-15抗体及其在制备药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH062075B2 (ja) * 1988-04-30 1994-01-12 大日本製薬株式会社 抗ヒトポストヘパリンプラズマ由来リポ蛋白リパーゼモノクローナル抗体およびその製造方法
CA2273823C (en) * 1996-12-06 2007-06-05 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polypeptides encoded by a human lipase-like gene, compositions and methods
WO1999032611A1 (en) * 1997-12-19 1999-07-01 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use
BR0009333A (pt) 1999-03-26 2002-01-08 Aventis Pharm Prod Inc Composição para reduzir a expessão do gene lipg e a atividade enzimática do polipeptìdeo de lipg, para inibir a atividade enzimática do polipeptìdeo de lipg., para aumentar o nìvel e a atividade enzimática de polipeptìdeo lipg em um paciente e métodos para aumentar o nìvel de colesterol de lipoproteìna de alta densidade e apolipoproteìna ai, para reduzir o nìvel de colesterol de lipoproteìna de densidade muito baixa e de colesterol ldl e colesterol vldl em um paciente, para diagnosticar uma predisposição para baixos nìveis de colesterol hdl e a apolipoproteìna ai, e para determinar se um composto de teste pode inibir a reação enzimática entre o polipeptìdeo de lipg e o colesterol hdl e apolipoproteìna ai e pode aumentar a reação enzimática entre o polipeptìdeo de lipg e o colesterol vldl e vdl
WO2013054830A1 (ja) * 2011-10-12 2013-04-18 塩野義製薬株式会社 Ｅｌの酵素活性を阻害するｅｌに対するモノクローナル抗体
CA2905597C (en) * 2013-03-14 2019-09-24 Shionogi & Co., Ltd. Monoclonal antibody inhibiting enzymatic activity of endothelial lipase

Also Published As

Publication number Publication date
AU2015313179B2 (en) 2020-10-22
EA201790590A1 (ru) 2017-08-31
JPWO2016039402A1 (ja) 2017-06-22
IL250981A0 (en) 2017-04-30
EP3192813A4 (en) 2018-08-01
WO2016039402A1 (ja) 2016-03-17
EA036324B1 (ru) 2020-10-27
KR20170052655A (ko) 2017-05-12
AU2015313179A1 (en) 2017-03-30
BR112017004429A2 (pt) 2018-02-27
US10570215B2 (en) 2020-02-25
TW201613982A (en) 2016-04-16
TWI734410B (zh) 2021-07-21
CN107074963B (zh) 2021-07-16
MY181835A (en) 2021-01-08
JP6635599B2 (ja) 2020-01-29
CL2017000595A1 (es) 2017-11-03
SG10201900605SA (en) 2019-02-27
US20200071424A1 (en) 2020-03-05
CN107074963A (zh) 2017-08-18
JP2020059743A (ja) 2020-04-16
TW202026313A (zh) 2020-07-16
EP3192813A1 (en) 2017-07-19
JP6827255B2 (ja) 2021-02-10
CA2960994A1 (en) 2016-03-17
ZA201702489B (en) 2018-08-29
SG11201701762VA (en) 2017-04-27
KR102520286B1 (ko) 2023-04-10
IL250981B (en) 2020-06-30
TWI688575B (zh) 2020-03-21
MX2017002968A (es) 2017-06-15
US11136411B2 (en) 2021-10-05
US20170260290A1 (en) 2017-09-14
PH12017500461A1 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
AR101811A1 (es) Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
BR112017017727A8 (pt) Heterociclos bicíclicos como inibidores de fgfr4
MX2018005829A (es) Composiciones para tratar el cabello.
BR112016022855A2 (pt) composições e métodos para modular a expressão de pkk
EA201692105A1 (ru) Новые пиразолопиримидиновые производные и их применение в качестве ингибиторов malt1
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
DK3334444T3 (da) Sammensætning af mælkesyrebakterier til anvendelse i behandling af infektioner, der skyldes propionibacterium acnes, og navnlig til acne
UY34676A (es) ?cuchillo para tratamiento de madera, métodos para galvanizado y tratamiento de superficies de cuchillo para tratamiento de madera?.
EA201692494A1 (ru) Композиции, содержащие липохитоолигосахарид и микроорганизм для усиления роста растения
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
CO2017011778A2 (es) Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
PH12016502001A1 (en) Novel bacteriophage and composition comprising same
BR112017000398A2 (pt) composto ou sal do mesmo, método de tratamento de uma infecção causada por dirofilaria immitis, e, kit.
EA201791716A1 (ru) Фармацевтический состав
BR112016023519A2 (pt) inibidor de sinalização de wnt/ß-catenina, composição farmacêutica e método de tratamento e/ou prevenção de uma patologia definida por malformação vascular
UY38352A (es) Inhibidores de integrina alfavbeta6
PH12016502000B1 (en) Novel bacteriophage and composition comprising same
MX2016011572A (es) Composiciones antimicrobianas de acido organico.
CL2015002642A1 (es) Anticuerpo monoclonal, inhibiendo la actividad enzimática de la lipasa endotelial vascular.
ES2721003T3 (es) Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis
BR112018006358A2 (pt) métodos de conservação da atividade biológica de ácidos ribonucleicos.